Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure

American Heart Journal

Volumn 152, Issue 1, 2006, Pages

  Gerlach, Raquel F ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

BLOOD SAMPLING; CLINICAL EXAMINATION; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DIAGNOSTIC TEST; ENZYME BLOOD LEVEL; LETTER; LEUKOCYTE; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION;

BIOLOGICAL MARKERS; HEART FAILURE, CONGESTIVE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 33745670405     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.04.022     Document Type: Letter

References (8)

1. George J., Patal S., Wexler D., et al. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150 (2005) 484-487
2. Jung K., Lein M., Laube C., et al. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 314 (2001) 241-244
3. Jung K., Laube C., Lein M., et al. Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin Chem 44 (1998) 1060-1062
4. Makowski G.S., and Ramsby M.L. Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma. Anal Biochem 322 (2003) 283-286
5. Gerlach R.F., Uzuelli J.A., Souza-Tarla C.D., et al. Effect of anticoagulants on plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 344 (2005) 147-149
6. Tanus-Santos J.E., and Gerlach R.F. Circulating matrix metalloproteinase-9 levels as a possible marker of aortic stiffness. Arterioscler Thromb Vasc Biol 25 (2005) e27
7. Tanus-Santos J.E., and Gerlach R.F. Serum samples should not be used to assess circulating matrix metalloproteinase-9 levels as a prognostic marker of disease. Int J Cancer 118 (2006) 789
8. Souza-Tarla C.D., Uzuelli J.A., Machado A.A., et al. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 38 (2005) 410-414